Document is current

Article History

Accepted: 17 November 2024

First Online: 18 January 2025

Declarations

:

: This study was supported by Teva Branded Pharmaceutical Products R&D, Inc.

: Samuel Frank and Claudia M. Testa served as co-principal investigators of the First-HD study. Samuel Frank was compensated for his professional role as the chair of the Data and Safety Monitoring Board for the KINECT-HD study. Jody Goldstein, Elise Kayson, Christine O’Neill, and Jacquelyn Whaley report no conflicts of interest. Blair R. Leavitt is an employee of the Department of Medical Genetics and Division of Neurology, Department of Medicine, and a senior scientist at the Centre for Molecular Medicine and Therapeutics, The University of British Columbia, and BC Children’s Hospital. In the last 5 years, he has held or applied for research grants in the area of neurodegenerative disease from the Canadian Institutes of Health Research, The Huntington Society of Canada, Weston Brain Foundation, Brain Canada, uniQure, Triplet Therapeutics, and the Nanomedicines Innovations Network. He has served on advisory boards for sRNAlytics, the Huntington’s Disease Society of America, and the Huntington Society of Canada. In addition, he has acted as a paid consultant for Roche, uniQure, Novartis, PTC Therapeutics, Triplet Therapeutics, Genentech, Takeda, and Ionis. He is also a shareholder, co-founder, and CEO of Incisive Genetics Inc. David Oakes has received research support from Auspex (for the First-HD and related studies), Vaccinex, Prana Pharmaceuticals, Biogen, and the National Institutes of Health, and received honoraria from Raptor Pharmaceuticals and Voyager Inc. Nicholas Gross, Nayla Chaijale, Steve Barash, and Mark Forrest Gordon are employees and shareholders of Teva Pharmaceuticals.

: Consistent with the policies of the Huntington Study Group, the corresponding author is confirmed as the guarantor of the work, and all authors had full access to the data. All authors have the right to publish any and all data separate and apart from any sponsor, and we take full responsibility for the data, the analysis and interpretation, and the conduct of the research.

: This article is based on previously conducted studies and does not contain any new studies with human participants. All involved study centers of the original trial (NCT01897896) received approval by local ethics committees and informed consent was received for all participants.

: Consent was obtained during the original clinical study and no new consent forms were required/collected for this analysis.

: Not applicable.

: Not applicable.

: S.F., N.C., and M.F.G. contributed to the drafting/revision of the manuscript for content, including medical writing for content, and had a major role in the conceptualization, data curation, methodology, data analysis, supervision, validation, and reviewing. C.T., J.G., E.K., and J.W. contributed to the drafting/revision of the manuscript for content, including medical writing for content, and had a major role in the acquisition of data and the analysis or interpretation of data. B.R.L. and C.O. had a major role in the acquisition of data. D.O., N.G., and S.B. contributed to the drafting/revision of the manuscript for content, including medical writing for content, and the analysis or interpretation of data. All authors reviewed and approved the final manuscript.